Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 15:13
Please select the service you want to use:
Smartlinks | FLYHT Aerospace Solutions Ltd. | News | Disaster and Accident | Natural Disaster | Meteorological Disaster | International News | Disaster and Accident | Natural Disaster | Meteorological Disaster | Finance | Security Markets | Security Markets | Company News | Securities Issuers | Aerospace Companies | Frankfurt Stock Exchange | OTC Markets | TSX Venture Exchange | Cboe Canada | Omega ATS | Lynx ATS | CSE Pure Trading | Nasdaq CX2 | Nasdaq CXC | TSX Alpha Exchange
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact